TScan Therapeutics
TCRX
90 hedge funds and large institutions have $126M invested in TScan Therapeutics in 2024 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 31 increasing their positions, 15 reducing their positions, and 16 closing their positions.
107% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 15
1% more funds holding
Funds holding: 89 → 90 (+1)
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
1.28% less ownership
Funds ownership: 85.9% → 84.63% (-1.3%)
39% less capital invested
Capital invested by funds: $208M → $126M (-$82.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Checkpoint Capital
San Francisco,
California
|
+$4.22M |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$2.32M |
| 3 |
BlackRock
New York
|
+$1.49M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$661K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$646K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.06M |
| 2 |
SC
Stempoint Capital
New York
|
-$4.29M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.08M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$549K |
| 5 |
Jane Street
New York
|
-$468K |
TCRX Hedge Fund Activity: Q4 2024 in Review
90 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q4 2024, worth a combined $126M — down 39% from $208M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new TCRX positions and 16 closed out — a net gain of 1 holder — while 31 added to existing stakes and 15 trimmed.
The largest buyer was Checkpoint Capital, adding an estimated $4.22M. The largest seller was Great Point Partners, exiting entirely with an estimated $5.06M sold.
- 90 institutional investors held TScan Therapeutics (TCRX) as of Q4 2024, up from 89 in Q3 2024.
- Funds reported $126M of TScan Therapeutics stock for Q4 2024, down 39% quarter-over-quarter.
- 17 funds opened new TScan Therapeutics positions in Q4 2024 and 16 closed out, a net change of +1 holder.
- The largest TScan Therapeutics buyer in Q4 2024 was Checkpoint Capital, an estimated $4.22M added.
- The largest TScan Therapeutics seller in Q4 2024 was Great Point Partners, an estimated $5.06M sold.
Based on aggregated 13F filings for Q4 2024.